MEPs AGAINST CANCER Seminar

Improving outcomes, driving efficiency in cancer care: How do we learn from best practice?

Schedule for the lunch seminar

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00–12:10</td>
<td>First course is served</td>
<td></td>
</tr>
<tr>
<td>12:10–12:25</td>
<td>Welcome, aims and objectives</td>
<td>Lieve Wierinck MEP</td>
</tr>
<tr>
<td>12:25–12:35</td>
<td>Brief introduction about MAC</td>
<td>Sakari Karjalainen, Association of European Cancer Leagues</td>
</tr>
<tr>
<td>12:35–12:50</td>
<td>Improving outcomes, driving efficiency in cancer care – the key issues for policymakers</td>
<td>Suzanne Wait, All.Can</td>
</tr>
<tr>
<td>12:50–13:10</td>
<td>How can this be done across the cancer care pathway? Examples of best practice from different countries and perspectives</td>
<td>Lydia Makaroff, European Cancer Patient Coalition (ECPC)</td>
</tr>
<tr>
<td>13:10–13:20</td>
<td>First course is cleared, main course is served</td>
<td></td>
</tr>
<tr>
<td>13:20–13:40</td>
<td>The ECCO paper on access to innovation: focusing on what makes the greatest difference to patients</td>
<td>Ian Banks, European CanCer Organisation (ECCO)</td>
</tr>
<tr>
<td>13:40–14:20</td>
<td>Round-table discussion: How can we amplify best practice examples across Europe – what is the role for the EU and Member States?</td>
<td>Moderated by Lydia Makaroff, ECPC; Panel: Amadou Diarra, Bristol-Myers Squibb; Herb Riband, Amgen; Ian Banks, ECCO; Commission representative (TBC); Pascal Garel, European Hospital and Healthcare Federation (HOPE); Rosna Mortuza, International Consortium for Health Outcomes Measurement</td>
</tr>
<tr>
<td>14:20–14:30</td>
<td>Policy response and conclusions</td>
<td>Lieve Wierinck MEP</td>
</tr>
</tbody>
</table>
KEY MESSAGES

1. There is an urgent need, and an opportunity, to improve the efficiency of cancer care.
2. Efficiency – and inefficiency – must be defined first and foremost by what matters to patients.
3. We need to have the courage to scrutinise what we are doing – and use data effectively to drive improvement.
4. The EU can play a key role in fostering exchanges of best practice between Member States.
5. The challenges to sustainable cancer care cannot be resolved by any stakeholder group alone.

INTRODUCTION BY HOSTING MEP

MEP Lieve Wierinck (ALDE, Belgium), a cancer survivor herself, and a strong advocate for better cancer care across Europe, passed a resolution on the European Semester in February 2017, to include measures aimed at improving efficiency in cancer care at the EU level. “How do we define ‘efficient cancer care?’ Focusing on outcomes that truly matter to patients, is a good place to start” said Wierinck. MEP Wierinck stressed the need to focus on solutions that have shown to improve efficiency across the entire care pathway – from small-scale efforts to system-wide changes and encouraged policy makers to adopt these practices in their countries.

The introductory note of MEP Wierinck was followed by a presentation of Dr. Sakari Karjalainen, President of ECL, who introduced the work and upcoming events of MEPs Against Cancer (MAC Group).

EXPERT PRESENTATIONS

I. Improving outcomes, driving efficiency in cancer care – key issues for policy-makers by Dr. Suzanne Wait, All.Can Secretariat

Dr. Suzanne Wait, Managing Director of All.Can, introduced the mission and vision of the initiative and underlined the urgent need for improving efficiency in cancer care. Dr. Wait stressed that across healthcare, 20% of spending is estimated to be wasted on ineffective interventions (WHO, The World Health Report 2010). According to the Commission DG for Economic and Financial affairs report on efficiency of healthcare systems in the EU (2015), reducing inefficiency could lead to an average gain of 2 life years in industrialised countries, Dr. Wait added.
II. Improving outcomes in cancer care pathway – examples and best practices by Lydia Makaroff, European Cancer Patient Coalition (ECPC)

Lydia Makaroff, Director of ECPC, showcased some powerful solutions to efficiency challenges, drawing from examples of best practices from different countries and across the cancer pathway. Her examples included (i) the necessity for HPV vaccination in girls and boys = prevention; (ii) child friendly screening for paediatric patients = diagnostics; (iii) benefits of early introduction of palliative care = treatment & palliative care; (iv) web based questionnaires for treated lung cancer patients = follow-up; and (v) support for survivors to return to work = rehabilitation and survivorship. Ms. Makaroff showed that even small changes in all aspects of treatment can result in large gains for patients.

III. Access to innovation – Ian Banks, European CanCer Organisation (ECCO)

Dr. Ian Banks, Chair of the Patient Advisory Committee at ECCO, said “we need to be innovative about innovation. It does not simply mean developing treatments but assessing the processes involved in cancer care. Patients must be involved in decisions regarding these processes.” He engaged with the audience in a discussion on different aspects of innovation.

MULTI-STAKEHOLDER PANEL

Dirk van den Steen of the European Commission’s health directorate (DG Sanete) commented on existing disparities in cancer outcomes, and inequalities in access to care across Europe. He noted the importance of presenting solutions to policymakers – versus solely highlighting existing challenges.

Dr. Ian Banks commented on the importance of listening to the patient perspective, that this is the starting point for improving efficiency, and outcomes. This was a clear consensus of the seminar.

Amadou Diarra, Head of Global Policy, Advocacy and Government Affairs at Bristol-Myers Squibb commented on the importance of industry’s involvement in multidisciplinary policy initiatives, such as All.Can.

Pascal Garel, Chief Executive of the European Hospital and Healthcare Federation (HOPE) spoke of the importance of changing attitudes and gathering evidence to inform the way care is provided. Only open attitudes and a respect for data can persuade individuals to promote real change across healthcare systems.

Rosna Mortuza, Director of Implementation at ICHOM, summarized the importance of being able to compare outcomes in cancer care using common measures and to create incentives within the system: “We need to shift from volume to value; incentivise outcomes to focus on value.”

Herb Riband, Vice President of International Policy & Government Affairs at Amgen, further reinforced this point, by saying: “We need to think about quality and efficiency if we want to think seriously about sustainability in cancer care.”

CLOSING REMARKS BY THE HOST

MEP Wierinck said: “We need to make sure our efforts are joined together – that we are efficient in our attempts to combat inefficiency. I believe that sometimes we do not all work together – and there are so many examples of good practice that could be replicated; so many good ideas that never make it across borders of Member States. The EU offers a huge opportunity for exchange and collaboration – we should take full advantage of this and look for solutions together.”